問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

Division of Radiation Therapy

Division of Radiology

Division of Thoracic Medicine

更新時間：2023-09-19

吳元宏Wu, Yuan-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

Recruiting Trial

7Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳元宏

List

15Cases

2017-01-20 - 2025-08-15

Phase III

A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)

  • Condition/Disease

    Locally Advanced Head and Neck Squamous Cell Carcinoma

  • Test Drug

    Keytruda

Participate Sites
10Sites

Terminated10Sites

楊慕華
Taipei Veterans General Hospital

Division of Radiation Therapy

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2022-08-31 - 2031-02-28

Phase III

A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplatin

  • Condition/Disease

    Head and Neck Cancer

  • Test Drug

    Xevinapant (Debio 1143)

Participate Sites
9Sites

Recruiting9Sites

2024-10-01 - 2026-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-08-14 - 2027-07-24

Phase III

A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  • Condition/Disease

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    DEBIO 1143

Participate Sites
10Sites

Recruiting8Sites

Terminated2Sites

2016-12-26 - 2021-04-08

Phase III

A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN THE FRONT-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    MSB0010718C 20mg/ml Solution for Infusion

Participate Sites
8Sites

Terminated7Sites

張牧新
Taipei Veterans General Hospital

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB